Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase 2 Study of Itacitinib or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer

NCT02257619 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT02257619
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02257619 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase 2 Study of Itacitinib or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer
Lead sponsor
Incyte Corporation
Phase
Phase 2
Overall status
Terminated
Start date
September 24, 2014
Completion date
April 5, 2016
Enrollment
9 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc (non-small cell lung carcinoma)